← Eichor
Study identifier: NCT06252233 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer

Condition: Lung Cancer · Quality of Life  ·  Sponsor: University of Bayreuth

PhaseNA
Planned participants220
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to determine whether a preference-oriented quality of life monitoring with defined diagnostic and therapeutic options improves quality of life in patients with lung cancer during routine follow-up care.

This description comes directly from the study's public registry record.

Talk to the study team

Martin Emmert, PhD, Prof.  ·  +49 160 92203562  ·  martin.emmert@uni-bayreuth.de

Monika Klinkhammer-Schalke, MD, Prof.  ·  +49-941-943-1803  ·  monika.klinkhammer-schalke@ur.de

Always discuss trial participation with your own doctor first.

Locations (8)

Klinikum BambergBamberg, GermanyRecruiting
Hospital BayreuthBayreuth, GermanyRecruiting
Klinikum Coburg GmbHCoburg, GermanyRecruiting
Caritas Krankenhaus St. Maria DonaustaufDonaustauf, GermanyRecruiting
Klinikum KulmbachKulmbach, GermanyRecruiting
Krankenhaus Barmherzige BrüderRegensburg, GermanyRecruiting
Universitätsklinikum RegensburgRegensburg, GermanyRecruiting
Klinikum St. Elisabeth StraubingStraubing, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06252233